SAB Biotherapeutics, Inc. [Rocket]

Overview

SAB Biotherapeutics, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
10/10/2023	3	Sessa Capital (Master), L.P. (Director) has filed a Form 3 on SAB Biotherapeutics, Inc.
10/10/2023	3	Form 3 - Initial statement of beneficial ownership of securities:
10/02/2023	8-K	Quarterly results
08/21/2023	S-3	Form S-3 - Registration statement under Securities Act of 1933:
08/21/2023	8-K	Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
08/21/2023	10-Q	Quarterly Report for the period ended June 30, 2023
08/14/2023	NT 10-Q	Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20
Revenues	60.9	55.2
Revenue growth	10.2%
Cost of goods sold	0.0	0.0
Gross profit	60.9	55.2
Gross margin	100.0%	100.0%
Research and development	57.2	27.9
General and administrative	17.1	6.8
EBIT	-13.4	20.6
EBIT margin	-22.0%	37.2%
Pre-tax income	-17.1	20.1
Income taxes	0.0	0.0
Tax rate	0.0%	0.0%
Net income	-17.1	20.1
Net margin	-28.2%	36.4%

Diluted EPS	($0.63)	$0.74
Shares outstanding (diluted)	27.3	27.0

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy